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Abstract
Background
Proliferative activity (Ki-67 Labelling Index) in breast cancer increasingly serves as an addi-
tional tool in the decision for or against adjuvant chemotherapy in midrange hormone recep-
tor positive breast cancer. Ki-67 Index has been previously shown to suffer from high inter-
observer variability especially in midrange (G2) breast carcinomas. In this study we con-
ducted a systematic approach using different Ki-67 assessments on large tissue sections in
order to identify the method with the highest reliability and the lowest variability.
Materials and Methods
Five breast pathologists retrospectively analyzed proliferative activity of 50 G2 invasive
breast carcinomas using large tissue sections by assessing Ki-67 immunohistochemistry.
Ki-67-assessments were done on light microscopy and on digital images following these
methods: 1) assessing five regions, 2) assessing only darkly stained nuclei and 3) consider-
ing only condensed proliferative areas (‘hotspots’). An individual review (the first described
assessment from 2008) was also performed. The assessments on light microscopy were
done by estimating. All measurements were performed three times. Inter-observer and
intra-observer reliabilities were calculated using the approach proposed by Eliasziw et al.
Clinical cutoffs (14% and 20%) were tested using Fleiss’ Kappa.
Results
There was a good intra-observer reliability in 5 of 7 methods (ICC: 0.76–0.89). The two high-
est inter-observer reliability was fair to moderate (ICC: 0.71 and 0.74) in 2 methods (region-
analysis and individual-review) on light microscopy. Fleiss’-kappa-values (14% cut-off)
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were the highest (moderate) using the original recommendation on light-microscope
(Kappa 0.58). Fleiss’ kappa values (20% cut-off) were the highest (Kappa 0.48 each) in ana-
lyzing hotspots on light-microscopy and digital-analysis. No methodologies using digital-
analysis were superior to the methods on light microscope.
Conclusion
Our results show that all methods on light-microscopy for Ki-67 assessment in large tissue
sections resulted in a good intra-observer reliability. Region analysis and individual review
(the original recommendation) on light-microscopy yielded the highest inter-observer reli-
ability. These results show slight improvement to previously published data on poor-repro-
ducibility and thus might be a practical-pragmatic way for routine assessment of Ki-67 Index
in G2 breast carcinomas.
Introduction
Proliferative activity and the use of genomic tests and their scores are getting increasing atten-
tion as they can be considered as further diagnostic tool additionally to traditional clinic-patho-
logical parameters obtained on routine histological examination of surgically resected breast
cancer specimens [1–3]. Especially midrange hormone receptor positive breast cancers may
pose diagnostic challenges, as the indication for or against adjuvant chemotherapy cannot be
met upon traditional clinic-pathological parameters in all instances [1–3]. The use of prolifer-
ative activity in hormone receptor positive breast cancers, measured by immunohistochemical
assessment of the Ki-67 antigen was previously suggested on a study conducted on a BIG-1-98
patient cohort [4, 5]. This study suggested that Ki-67 labeling index (LI) above 14% is a poten-
tial marker in the decision for adjuvant chemotherapy, as Ki-67 LI>14% may identify patients
who may benefit from adjuvant chemotherapy [5]. In the meantime, the assessment of Ki-67
fraction on the histological slide in routine pathological diagnostics already serves as a decision
tool for or against chemotherapy in hormone receptor positive breast cancer. Nevertheless, in-
consistency in Ki-67 assessment in moderately differentiated breast cancer is widely observed
and the use of Ki-67 biomarker is controversially discussed as a parameter for treatment deci-
sions in such breast cancer patients. There are some studies so far describing the inconsistency
in Ki-67 assessment in routine diagnostic in breast cancer [3, 6–11]. Despite recommendations
from the International Ki-67 in Breast Cancer Working Group the inter-observer variability of
routine Ki-67 assessment in breast cancer remains poor to moderate especially in the G2 breast
cancer group (Kappa: 0.2–0.4) [3, 8–12]. The Swiss Working Group of Breast- and Gyneco-
pathologists has surveyed inter- and intra-observer consistency of Ki-67-based proliferative
fraction in breast carcinomas and showed good to very good agreement in well (G1) and
poorly (G3) differentiated breast carcinomas [3]. However, there was a high degree of inter-
and intra-observer inconsistency in the read-outs of Ki-67 (LI) in moderately differentiated
(G2) carcinomas, which is particularly problematic because it is for these “intermediate” carci-
nomas where guidance from the carcinoma’s proliferative activity is expected for chemothera-
py decisions [3, 13,1].
In our study we addressed the question whether a systematic further analysis of different
counting methods, based on the problematic issues identified in the previous study of the Swiss
Working Group of Gyneco- and Breast-Pathologists can improve the unsatisfactory inter- and
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intra-observer reliability in Ki-67 LI in midrange breast cancer [3]. We systematically analyzed
Ki-67 LI on 50 midrange breast cancers applying different counting methods using light mi-
croscopy and digital analyses. As endpoint of the study, Ki-67 LI assessment expressed in % ac-
cording to the different methods was aimed. Intra- and inter-observer reliabilities with these
values were calculated and the best reproducible way to assess Ki-67 LI to determine was the
end goal of the study.
Materials and Methods
Study objective
The main goal of the study was to establish the most reproducible method of assessing prolifer-
ative activity (Ki-67 labeling index) in moderately differentiated breast carcinomas (G2), reach-
ing the highest reproducibility.
Study design
Five experienced breast pathologists participated in the study and assessed Ki-67 LI on whole
tissue sections containing midrange invasive breast carcinoma following eight assessment
methodologies. Exact description of the methods is described below (Assessment methods of
Ki-67 LI). The experts were breast pathologists and also members of the Working Group of the
Gyneco- and Breast-Pathologist of the Swiss Society of Pathology. Each expert used her/his
own light microscope for the methods A, C, E and G. The samples were assessed three times
with an interval of at least 2 weeks between the repetitions (Fig 1)
Patients’ cohort
We retrospectively identified 50 breast cancer patients for the study from the Institute of Surgi-
cal Pathology, University Hospital Zurich, Switzerland (n = 50). All 50 cancers were moderate-
ly differentiated (G2) breast carcinomas by Elston and Ellis [14]. All patients were female,
median age was 62.7 years (range: 37 to 83 years). 35 of 50 tumors were histologically invasive
ductal carcinomas (no special type, NST), 11 of 50 cases were invasive lobular carcinomas and
4 of 50 cases corresponded to special subtypes (2 mucinous carcinomas, 1 micropapillary carci-
noma and 1 metaplastic carcinoma). Except one case (a triple negative metaplastic carcinoma)
all carcinomas were hormone receptor positive and Her2 negative. Histological tumor stage
was seen as follows: 25 of 50 cases were pT1, 22 of 50 cases were pT2 and 3 cases were pT3.
35 of 50 cases were nodal negative, 15 of 50 cases were nodal positive. 12 of 50 cases were multi-
focal tumors. None of the patients underwent preoperative chemotherapy. Patients were select-
ed for the study, if postoperative surgical specimen with sufficient invasive carcinoma tissue
(minimum 5 mm invasive carcinoma) was available.
This project is a part of a retrospective breast cancer study on archived human tissue materi-
al, which was approved by the Ethical Committee of the Canton Zurich (ZH-KEK-2012-553).
Additional informed consent was not necessary as the ethical approval covered the ethical is-
sues of the retrospective study and the samples were all anonymized and de-identified prior to
the study. The Ethical Committee of the Canton Zurich specifically approved this study includ-
ing the study protocol.
Immunohistochemistry for Ki-67 and digital image analysis
The 50 paraffin blocks containing tumor tissue were re-cut and re-stained for Ki-67 according
the following laboratory parameters (protocol Institute of Surgical Pathology, University Hos-
pital Zurich, Switzerland, Laboratory for in-situ technology): 2 micrometers slides were cut
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from paraffin-blocks, which contained formalin fixed tumor tissue. During the whole staining
procedure the slides were treated with the fully automated Benchmark staining system (Ven-
tana Medical Systems) using the primary antibody (rabbit monoclonal anti-Ki-67 human,
clone 30–09 Ventana Medical Systems, Inc). The immunohistochemichal procedures were car-
ried out at the same time on the empty slides from each paraffin block.
From each tumor sample the participating pathologists received one H&E stain and one Ki-
67 immunostain. All Ki-67 immunostains of the principal investigator (Z.V) were scanned in
the Institute of Surgical Pathology, University Hospital Zurich. The digital links containing the
immunostains were provided to the participating pathologists, which were blinded for the re-
sults of the assessment of others. The computer software used for the methods C, E and G is
the validated ImmunoRatio web-based software for quantitative image analysis of Ki-67 immu-
nohistochemistry in breast cancer tissue section [15].
Statistical analysis
Inter- and intra-observer reliability, denoted by ρinter and ρintra, were estimated using the ap-
proach proposed by Eliasziw et al. [16]. Weighted sum of inter- and intra-observer reliability
Fig 1. Study design. A) Summary of study design and decision making. B) Summary of methodologies used for the Ki-67 assessment.
doi:10.1371/journal.pone.0123435.g001
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was calculated for each method using the pre-specified weight factor 0.6 (for inter-observer re-
liability) and 0.4 (for intra-observer reliability). P-values were calculated based on the
confidence bounds.
Additionally, Fleiss’ kappas based on different clinically established cut-offs (14% and 20%)
were estimated along with their lower 95% confidence bounds and p-values, which were com-
puted using bias-corrected bootstrap methods.
Multiple testing corrections were not applied on these p-values, thus the results are
considered exploratory.
Determination of sample size
The purpose of this study was to select the best method in terms of concurrent assessment of
inter- and intra-observer reliability where 5 raters took repeated measurements in a series of
tumor samples. The method proposed by Eliasziw et al. can be applied in this situation, so that
“both sources of error (inter-rater and intra-rater) are simultaneously incorporated into the re-
sulting statistical analysis” and “each individual measurement contributes to the estimation of
both inter-rater and intra-rater reliability coefficients” [16]. According to the recommendation
by Elasziw, for our study 50 study samples, 5 observers and 3 repetitions were more than suffi-
cient to test a reliability hypothesis (H0: ρinter0.6 versus H1: ρinter>0.6; H0: ρintra0.6 versus
H1: ρintra>0.6) at the 5% significance level with 80% power [16], under the assumption that
the effect size was 0.15. (Fig 1A)
Assessment methods of Ki-67 labelling index (Fig 1B)
Method A: individual review. The percentage of cells showing definite nuclear immuno-
reactivity among 2,000 invasive neoplastic cells in randomly selected, high-power (magnifica-
tion, ×400) fields at the periphery of the tumor was calculated on light microscope using the
originally recommended criteria [4, 5, 17]. Definite nuclear positivity was defined as any stain
independently from the stain intensity as defined by Dowsett et al. and Viale et al. earlier [4, 5,
17]. No hot spots were selected for this analysis.
Method B: “region” assessment on image analysis. Comparative analysis of five random
fields within the tumor (both periphery and center) (n = appr. 500 cells) using the digital links
with Ki-67 stains on the computer screen and the online tool (ImmunoRatio).
Method C: “region” analysis on light microscope. Comparative analysis of five random
fields within the tumor (both periphery and center) (n = appr. 500 cells) using the own light
microscope on 20x magnification.
Method D: “hotspot” assessment on image analysis. Analysis of five random fields with
the highest index (hotspots) within the tumor (n = appr. 500 cells) using the digital links with
Ki-67 stains on the computer screen and the online tool (ImmunoRatio).
Method E: “hotspot” analysis on light microscope. Analysis of five random fields with
the highest index (hotspots) within the tumor (n = appr. 500 cells) using the own light micro-
scope on 20x magnification.
Method F: “threshold intensity” assessment on image analysis. Comparative analysis of
five peripheral fields assessing only darkly stained nuclei (n = appr. 500 cells) using the digital
links with Ki-67 stains on the computer screen and the online tool (ImmunoRatio).
Method G: “threshold intensity” analysis on light microscope. Comparative analysis of
five peripheral fields assessing only darkly stained nuclei (n = appr. 500 cells) using the own
light microscope on 20x magnification.
Method H: consensus review. All slides together are assessed on the multi-head micro-
scope using the three following methods: “no hotspot” (defined above as individual review),
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“region” analysis on microscope and “hotspot” analysis on microscope. From these 3 methods,
one single value was attributed as the Ki-67 index by making a majority approval.
The way of Ki-67 assessment. Methods A/C/E/G/H: eyeballing (estimation).
Methods B/D/F: positive and negative Ki-67 areas by image analysis (links to Ki‐67 stains
were provided via email, web‐software: ImmunoRatio). The online tool was used by all raters
at the standard pre-calibrated basic modus, following the instructions of the software. The area
of the histological section was determined by the individual raters based on the definition
above. The counting of the areas was done automatically by the software.
At 40x magnification on the microscope, in solid tumors, there are approx. 300‐400 cells de-
tectable for the measurements. (Fig 2)
Dropouts. Due to missing assessments from one expert, only assessments from 4 experts
were considered in the statistical analysis.
Since method H was very time-consuming and required that all experts were present during
the assessment, it was not possible to conduct this assessment and thus method H was not con-
sidered for the analysis.
Interpretation of ICC and Fleiss’ kappa. The calculation of inter-observer reliability ac-
cording to Eliasziw et al [16], is a generalized version of the ICC. We used the scale of the ICC
to interpret the results. For each method, we estimated the inter- and intra-observer reliability
by considering the expert to be random. Two reasonable scales for the interpretation of ICC
and Fleiss’ kappa are shown in Table 1.
Results
The statistical analysis was completed with the data of four experts using seven methods (A—
G) with following results:
Fig 2. Illustration of different Ki-67 assessment methods. A) Analysis of hotspots. B) Analysis of different areas. C) Analysis of only darkly stained nuclei.
doi:10.1371/journal.pone.0123435.g002
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Results of inter- and intra-observer reliability (Illustrated in Figs 3 and 4,
details shown in Table 2A)
P-values were calculated based on the null hypothesis that the agreement (Inter- and intra-ob-
server reliability/Fleiss’ kappa) 0.6.
Inter-observer reliability. The inter-observer reliability was fair to good in all methods.
The two highest inter-observer reliabilities were measured by methods which were carried out
on the light microscope. Method A (individual review on microscope), reaching 0.71 and
method C (region analysis on microscope by assessing regions only) reaching 0.74 were the
best methods. The highest inter-observer reliability on the image analysis was received by
method B (region assessment by image analysis) reaching 0.63.
The intra-observer reliability. The intra-observer reliability was excellent in Methods A/
C/E/F/G, reaching 0.76–0.89 and it was fair to good in Methods B/D reaching 0.69 resp.0.72.
Weighted sum of inter- and intra-observer reliability. Six out of seven methods (A/B/C/
D/E/G) reached a minimum of 0.6 as the weighted sum of the inter- and intra-observer vari-
ability. The weighted sum of inter- and intra-observer reliability was excellent in methods A
and B and fair to good in the other methods.
Summary of inter-and intra-observer reliability. The best methods as the result of the
weighted sum are methods A (individual review on microscope) and C (region analysis on mi-
croscope). None of the methods by image analysis was superior to the methods which were car-
ried out on the microscope.
Fleiss’ kappa in terms of reproducibility of the clinically used cut-offs of
14% and 20%, respectively (in Table 2B)
Fleiss’ kappa in terms of reproducibility of 14% cut-off. The reproducibility of the 14%
cut off was moderate in five methods (A/B/C/D/G) and fair in two methods (E/F). The highest
value of 0.58 was reached by method A (individual review on microscope).
Fleiss’ kappa in terms of reproducibility of 20% cut-off. The reproducibility of the 20%
cut off was moderate in two methods (D/E), fair in three methods (A/B/C) and slight in two
methods (F/G). The highest value of 0.48 was reached by methods D/E (hotspot analysis on mi-
croscope and on image analysis).
Table 1. Interpretation of ICC from Rosner (A) and Fleiss‘ kappa from Landis and Koch (B).
A
ICC Interpretation of ICC from Rosner
< 0.4 Poor agreement
0.4–0.75 Fair good agreement
0.76–1.00 Excellent agreement
B
Kappa Interpretation of Fleiss‘ kappa from Landis and Koch
< 0 Poor agreement
0.01–0.20 Slight agreement
0.21–0.40 Fair agreement
0.41–0.60 Moderate agreement
0.61–0.80 Substantial agreement
0.81–1.00 Almost perfect agreement
doi:10.1371/journal.pone.0123435.t001
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Summary of Fleiss’ kappa values in 14% and 20% cut-off. In general, slight to moderate
agreement was observed, with higher values for the 14% cut-off. The highest Fleiss’ kappa
(0.58) was observed for method A (individual review on microscope) with a 14% cut-off.
Discussion
In our study we addressed the question whether we can identify a methodology for breast can-
cer proliferative activity using Ki-67 immunohistochemistry with an improved intra- and
inter-observer variability. We have set up a design on whole tissue sections and applied seven
Fig 3. Bland Altmann plots for method A.
doi:10.1371/journal.pone.0123435.g003
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assessment methodologies using light microscope and digital image analysis. We could show in
our study that inter-observer reliability was improved and reached the highest (yet still moder-
ate) value when the analyses were carried out on the light microscope and the methodology in-
cluded the analysis of regions and of the original recommendation [4, 5]. In terms of
reproducibility of clinically relevant and previously established cut-offs for Ki-67 LI the highest
agreement of cut-off 14% (yet moderate) was achieved when using light microscope and apply-
ing the original recommendation for Ki-67 LI assessment [2, 4, 18]. The clinically recently in-
troduced cut-off of 20% Ki-67, could not superiorly be reproduced in this study, even though
Fig 4. Bland Altmann plots for method C.
doi:10.1371/journal.pone.0123435.g004
Breast Cancer Ki-67 Assessment Standardization
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analyzing hotspots (both on light microscope and image analysis) reached the highest (yet
moderate) reproducibility, which was inferior to the Fleiss’ kappa values achieved at the 14%
cut-off. No methodology by image analysis was superior to the methods applied on the light
microscope in our study.
The current study and the results represent slight improvement compared to previously
published reproducibility studies [3, 8, 9, 11]. These studies, including the first reproducibility
study of the Swiss Working Group of Gyneco- and Breast Pathologists, reported poor to fair
agreement on Ki-67 LI assessment in midrange breast cancer, with Kappa values ranging from
0.04–0.36 [3, 8, 9, 11]. Based on the first reported data, no single factor of Ki-67 assessment
could be attributed to poor reproducibility, however, it was generally the view, that the failure
in reproducibility of Ki-67 Li is due to a combination of factors as the area choice for the assess-
ment, intratumoral heterogeneity, differences in preanalytical or laboratory procedures or to
the definition what constitutes a positive cell [3]. Other studies pointed out the potential influ-
ence of different antibodies on Ki-67 LI. These data however are conflicting in terms of signifi-
cant influence, varying from relevant to no significant impact on percentage of stained cells [6,
11]. In 2011, the International Ki-67 in Breast Cancer Working Group reported a first recom-
mendation on Ki-67 Li assessment, which addressed also the handling of heterogeneous tumor
areas and the presence of as condensed areas, so called hot-spots within the tumor [17]. Despite
these guidelines, which incorporated the originally described counting methodologies in Ki-67
LI assessment, there has been no major break-through in terms of a reliable and reproducible
method in Ki67 assessment in midrange hormone positive breast cancer until now [4, 17]. The
second study of the International Ki-67 in Breast Cancer Working Group conducted a tissue
micro array based reproducibility study and showed excellent inter-laboratory and intra-labo-
ratory reliability [10], which very well corroborates our current data on whole tissue sections.
Five of the seven methodologies we tested in this study resulted in a good intra-observer
Table 2. Summary of inter- and intraobserver reliabilities (A) and Fleiss‘ kappas based on different cut-offs (B).
A
Method Inter-Observer Reliability Intra-Observer Reliability Weighted Sum of inter and intra-observer reliability Ranking ‘best method’
A 0.71 0.88 0.778 1*
B 0.63 0.72 0.666 5*
C 0.74 0.82 0.772 2*
D 0.57 0.69 0.618 6*
E 0.55 0.89 0.686 3*
F 0.40 0.76 0.544 7
G 0.60 0.81 0.684 4*
B
Method Fleiss’ kappa < = 14vs>14 Fleiss’ kappa < = 20vs>20
A 0.58 0.36
B 0.51 0.37
C 0.52 0.38
D 0.44 0.48
E 0.40 0.48
F 0.29 0.19
G 0.44 0.14
*: the method reached the requirements of the validation in the next step. The methods whose weighted sum of estimated inter- and intra-observer
reliability was larger than 0.6 were in principle qualiﬁed to be validated in a further phase of the study.
doi:10.1371/journal.pone.0123435.t002
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reliability. Probably this was due to the fact that pathologists most likely analyze morphological
tissue sections and immunohistochemical reactions in a similar yet individual way. As to inter-
observer reliability, the study by Polly et al showed that local or central assessment of Ki-67 Li
was only moderate (ICC varying from 0.59 to 0.71) even though the study used tissue micro ar-
rays, where knowingly intratumoral heterogeneity poses less importance theoretically [10].
The results on inter-observer reliability in our own current study yielded very similar results,
with ICC being 0.73 at highest. It is suffice to say though, that the methods in our study, with
ICC>0.60 were achieved on whole tissue sections using light microscopy and considering
analyses of different regions. This is most likely explainable in that way that an average value of
Ki-67 LI on low-power magnification most likely reflect a doable way to evaluate the whole sec-
tion and draw an average of the stained cells from the tumor periphery respectively from the
invasion front. On the other hand, we need to state that pre-analytical variations were excluded
in our study, as all stains were performed in a central laboratory in Zurich, all slides from each
block being incubated during the same procedure. Nevertheless, the issue of pre-analytical vari-
ables and interpretational differences needs to be kept in mind, when comparing results be-
tween different institutions and/or individual raters, as pointed out previously in the literature
[3, 19]. None of the methods using digital image analysis were superior to the methods on light
microscope in our study.
The reproducibility of clinically relevant cut-offs has been also the subject of some recent
studies [19]. In a study of the European Working Group of Breast Screening Pathology, the
provided Ki-67 LI-s of the participating institutions were clustered around numbers ending
with 0 or 5, questioning the realistic reproducibility of cut-offs different from these numbers
[19]. The original recommendation of Ki-67 LI assessment in 2008 set a cut-off of 14% for pa-
tients, who benefited from a chemotherapy [4]. Even though the reproducibility of the 14%
cut-off poses a diagnostic challenge at the moment, the only method in our study, yielding the
highest Fleiss’ kappa values, was the 14% cut-off using the recommendation by Viale at al from
2008 [4]. The recently recommended cut-off of 20% was inferior in the reproducibility for the
14% cut-off in our study [2].
Clinical guidelines increasingly incorporate the potential or recommended use of Ki-67 LI
in the clinical oncological decision algorithm, although caution is drawn to the still relevant re-
producibility issues in midrange breast cancer in routine histopathological diagnostics [1, 2,
13]. Along with the recommendation of current German guidelines, very similar to our own
observations from 2012, the degree of Ki-67 LI can be reliably assessed and reproduced in low-
and high ranges, however, caution is needed in mid-range breast carcinomas when dealing
with an adjuvant oncological situation [1, 3, 13]. The impact of Ki-67 LI in neoadjuvant setting,
especially in triple negative breast cancer, nevertheless has level I evidence and is increasingly
applied in core biopsies in the neoadjuvant setting [1, 13, 20].
Genomic tests versus Ki-67 LI as the best method to predict clinical response remains an
issue to be further explored [1, 13, 20]. Varying degree of agreement between Ki-67 LI and ge-
nomic scores were reported in the literature, which at the current moment addresses the need
for further analytical and comparative studies in that field [21–24].
In summary, we could show in our study, that moderate improvement in the inter-observer
reproducibility of Ki-67 LI in midrange breast cancer was possible when applying standardized
pre-analytical procedures and using light microscopy on whole sections under consideration of
regional analyses. None of the methods by chosen image analysis were superior to the measure-
ments on the light microscope. This improvement in inter-observer reliability even though
moderate, is promising and needs to be further validated in different patient cohorts and incor-
porating clinical variables.
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